Business Context and Reporting Period
This Form 8-K, dated December 17, 2025, reports that Cartesian Growth Corporation III ("CGC"), a Cayman Islands exempted company and special purpose acquisition company (SPAC), has entered into a Business Combination Agreement with Factorial Inc., a Delaware corporation specializing in solid-state battery technology. The transaction is expected to close in mid-2026, subject to shareholder approvals and customary closing conditions. Upon closing, CGC will domesticate as a Delaware corporation and change its name to "Factorial Holdings, Inc."
Key Financial Metrics and Transaction Terms
- Implied Equity Value: The transaction values Factorial at an implied fully-diluted equity value of $1,100,000,000.
- PIPE Financing: CGC has secured $100,000,000 in gross proceeds through a Private Investment in Public Equity (PIPE) financing. This includes $25,000,000 from a Sponsor Investor and $75,000,000 from an Institutional Investor.
- Shareholder Redemptions: CGC Class A shareholders have the right to redeem their shares for cash equal to the pro rata portion of funds in the trust account (including interest).
- Warrant Exercise Price: Existing CGC warrants are exercisable for one Class A ordinary share at $11.50 per share.
- Financial Performance: The filing does not provide specific revenue, profit, cash flow, or margin figures for Factorial or CGC. It notes that Factorial is an early-stage company with a history of financial losses and expects to incur significant expenses.
Material Changes and Transaction Structure
The primary material change is the agreement to merge CGC and Factorial. The transaction structure involves:
- Domestication: CGC will transfer from the Cayman Islands to Delaware.
- Merger: A merger subsidiary will merge with Factorial, with Factorial surviving as a wholly-owned subsidiary of the new entity.
- Exchange Ratio: Factorial common stock will convert into New Factorial Series A Common Stock based on the $1.1 billion valuation.
- Equity Incentives: A new equity incentive plan will be adopted, reserving 15% of fully-diluted shares for issuance, and an employee stock purchase plan reserving 2%.
- Lock-Up Provisions: Sponsor and certain Factorial stockholders are subject to lock-up periods ranging from 180 days to one year post-closing, with potential early release based on trading price conditions.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Factorial is described as a leader in solid-state battery technology with validated cells tested in real-world scenarios, including a Mercedes-Benz EQS achieving over 1,200 km of range. The company is expanding into defense, aerospace, and robotics. Management anticipates the closing in mid-2026.
Risks and Contingencies:
- Development Risks: Battery development is complex; timing cannot be assured, and delays could adversely affect the business.
- Financial Risks: Factorial has a history of losses and may be unable to control costs or accurately estimate future supply and demand.
- Regulatory and Legal Risks: The transaction is subject to HSR Act clearance, SEC approval of the registration statement, and Nasdaq listing approval. Governmental trade controls and patent validity are also cited as risks.
- Transaction Risks: The deal may be terminated if shareholder approvals are not obtained, if a material adverse effect occurs, or if the closing does not occur by November 12, 2026.
Investor Verification Checklist
- Verify the final redemption rate of CGC shareholders, as this will impact the net cash available to the combined company.
- Confirm the status of the $100 million PIPE financing and the specific terms of the Institutional Investor commitment.
- Review the upcoming Form S-4 registration statement for detailed financial projections and risk factors not fully elaborated in this 8-K.
- Monitor the progress of regulatory approvals, specifically the HSR Act waiting period and Nasdaq listing approval.
- Assess the technical validation of Factorial's solid-state battery technology and the timeline for commercial production versus the current testing phase.